Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Payables (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Payables for 6 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Payables rose 23.47% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, up 23.47% year-over-year, with the annual reading at $5.0 million for FY2025, 23.47% up from the prior year.
  • Payables for Q4 2025 was $5.0 million at Janux Therapeutics, up from $3.4 million in the prior quarter.
  • The five-year high for Payables was $5.0 million in Q4 2025, with the low at $354000.0 in Q2 2021.
  • Average Payables over 5 years is $2.6 million, with a median of $2.5 million recorded in 2021.
  • The sharpest move saw Payables skyrocketed 747.46% in 2022, then plummeted 36.33% in 2023.
  • Over 5 years, Payables stood at $2.5 million in 2021, then fell by 12.16% to $2.2 million in 2022, then grew by 12.27% to $2.4 million in 2023, then skyrocketed by 66.09% to $4.0 million in 2024, then grew by 23.47% to $5.0 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $5.0 million, $3.4 million, and $3.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.